The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ<sup>®</sup>) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection

The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ<sup>®</sup>) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection

The first vaccine against chikungunya virus (CHIKV) was recently licensed in the U.S., Europe, and Canada (brand IXCHIQ<sup>®</sup>, referred to as VLA1553). Other pathogenic alphaviruses co-circulate with CHIKV and major questions remain regarding the potential of IXCHIQ to confer cross...

Full description

Bibliographic Details
Main Authors: Whitney C. Weber, Zachary J. Streblow, Craig N. Kreklywich, Michael Denton, Gauthami Sulgey, Magdalene M. Streblow, Dorca Marcano, Paola N. Flores, Rachel M. Rodriguez-Santiago, Luisa I. Alvarado, Vanessa Rivera-Amill, William B. Messer, Romana Hochreiter, Karin Kosulin, Katrin Dubischar, Vera Buerger, Daniel N. Streblow
Format: Article
Language:English
Published: MDPI AG 2024-08-01
Series:Vaccines
Subjects:
chikungunya virus (CHIKV)
alphaviruses
IXCHIQ
vaccine
cross-neutralization
antibody
Online Access:https://www.mdpi.com/2076-393X/12/8/893

Internet

https://www.mdpi.com/2076-393X/12/8/893

Similar Items